Summit Therapeutics: The High Stakes Of Translating China Clinical Data To The U.S.
Summit Therapeutics needs HARMONi-3 and Western-subgroup data to validate China-based ivonescimab results, while $690.7 million in Q2 cash…
Stephen Ayers 9 clicksNASDAQ
Summit Therapeutics Inc.
SMMT
2 stories
$14B Market cap · 2026-10-06
Stephen Ayers 9 clicks
The last Bristol Myers' blog post was wrong on the core thesis
Ivonescimab plus chemotherapy extended median overall survival by 4.2 months versus Tevimbra plus chemotherapy in HARMONI-6, challenging…
